Who is sponsoring NCT03340415?

NCT03340415 is sponsored by North District Hospital.

What drugs are being tested in NCT03340415?

Interventions in NCT03340415: Accelerated Rehabilitation plan.

What condition does NCT03340415 study?

NCT03340415 studies Hallux Valgus and Bunion.

Is NCT03340415 still recruiting?

NCT03340415 is currently completed. Last updated 24 March 2021.

Are results published for NCT03340415?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-24 · How we verify

NCT03340415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Timing of Weight Bearing After Hallux Valgus Surgery

Completed NA Results posted Last updated 24 March 2021

What this trial tests

NA trial testing Accelerated Rehabilitation plan in Hallux Valgus and Bunion in 53 participants. Completed in 30 April 2020.

Timeline

13 July 2018

Primary endpoint
30 June 2019

30 April 2020

Quick facts

Lead sponsor	North District Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	53
Start date	13 July 2018
Primary completion	30 June 2019
Estimated completion	30 April 2020
Sites	1 location across Hong Kong

Drugs / interventions tested

Accelerated Rehabilitation plan

Conditions studied

Hallux Valgus and Bunion — all drugs for Hallux Valgus and Bunion →

Sponsor

North District Hospital

Who can join

18 and older, any sex, with Hallux Valgus and Bunion. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Hallux Valgus Angle as a Measure of the Radiological Changes Primary · 0, 12, 26 weeks post-surgery

Weight bearing feet X-Ray to measure radiological parameters of hallux valgus. A larger angle represents the more severe condition. This is the angle between the 1st metatarsal and the proximal phalanx.

0 week

Group	Value	95% CI
Control Rehab	35.6	± 7.1
Accelerated Rehab	37.4	± 8.0

12 week

Group	Value	95% CI
Control Rehab	8.8	± 5.2
Accelerated Rehab	7.2	± 4.8

26 week

Group	Value	95% CI
Control Rehab	11.6	± 7.6
Accelerated Rehab	10.5	± 6.2

Inter-metatarsal Angle as a Measure of the Radiological Changes Primary · 0, 12, 26 weeks post-surgery

Weight bearing feet X-Ray to measure radiological parameters of hallux valgus. A larger angle represents the more severe condition. This is measure using the bisecting line between the 1st metatarsal and the 2nd metatarsal.

0 week

Group	Value	95% CI
Control Rehab	14.0	± 3.0
Accelerated Rehab	16.4	± 3.7

12 week

Group	Value	95% CI
Control Rehab	6.2	± 1.9
Accelerated Rehab	7.2	± 2.2

26 week

Group	Value	95% CI
Control Rehab	7.7	± 2.7
Accelerated Rehab	7.3	± 2.4

Radiological Changes (Tibial Sesamoid Position) Primary · 0, 12, 26 weeks post-surgery

Weight bearing feet X-Ray to measure radiological parameters of hallux valgus. 4 represents the most neutral position. bigger difference from 4 means more severe condition. This a score from 0-7.

0 week

Group	Value	95% CI
Control Rehab	5.55	± 1.2
Accelerated Rehab	5.6	± 1.1

12 week

Group	Value	95% CI
Control Rehab	2.6	± 1.2
Accelerated Rehab	3.0	± 0.9

26 week

Group	Value	95% CI
Control Rehab	2.9	± 1.3
Accelerated Rehab	3.0	± 1.0

Foot Function (FAOS Symptoms) Secondary · 0, 12, 26 week post-surgery

Calculation of foot function using the self-reported Foot and Ankle Outcome Score (FAOS): FAOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport and Recreation), and foot and ankle-related Quality of Life (QOL). The last week is taken into consideration when answering the questionnaire. Standardized answer options are given (% Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

0 week

Group	Value	95% CI
Control 6-wk NWB	58.3	± 26.1
Early 2 Week NWB	47.5	± 23.9

12 week

Group	Value	95% CI
Control 6-wk NWB	62.1	± 16.1
Early 2 Week NWB	76.9	± 13.6

26 week

Group	Value	95% CI
Control 6-wk NWB	81.9	± 11.8
Early 2 Week NWB	80.5	± 15.6

Foot Function (FAOS Pain) Secondary · 0, 12, 26 week post-surgery

0 week

Group	Value	95% CI
Control 6-wk NWB	44	± 23.8
Early 2 Week NWB	47.5	± 28.8

12 week

Group	Value	95% CI
Control 6-wk NWB	66.4	± 19.3
Early 2 Week NWB	78.6	± 11.4

26 week

Group	Value	95% CI
Control 6-wk NWB	82.2	± 15.6
Early 2 Week NWB	85.5	± 12.9

Foot Function (FAOS ADL) Secondary · 0, 12, 26 week post-surgery

0 week

Group	Value	95% CI
Control 6-wk NWB	59.7	± 29.4
Early 2 Week NWB	53.0	± 25.6

12 week

Group	Value	95% CI
Control 6-wk NWB	61.4	± 17.3
Early 2 Week NWB	81.4	± 7.6

26 week

Group	Value	95% CI
Control 6-wk NWB	84.3	± 10.6
Early 2 Week NWB	86.0	± 8.2

Foot Function (FAOS Sport) Secondary · 0, 12, 26 week post-surgery

0 week

Group	Value	95% CI
Control 6-wk NWB	52.1	± 29.7
Early 2 Week NWB	39.8	± 26.7

12 week

Group	Value	95% CI
Control 6-wk NWB	NA	± NA
Early 2 Week NWB	NA	± NA

26 week

Group	Value	95% CI
Control 6-wk NWB	76.7	± 15.7
Early 2 Week NWB	77.6	± 13.7

Foot Function (FAOS QoL) Secondary · 0, 12, 26 week post-surgery

0 week

Group	Value	95% CI
Control 6-wk NWB	41.2	± 30.2
Early 2 Week NWB	31.1	± 23.6

12 week

Group	Value	95% CI
Control 6-wk NWB	49.1	± 20.4
Early 2 Week NWB	72.6	± 20.7

26 week

Group	Value	95% CI
Control 6-wk NWB	82.4	± 11.2
Early 2 Week NWB	81.4	± 14.9

Sponsor's own description

Investigate the optimal timing for weight bearing after Hallux Valgus surgery. Hypothesis: Early weight bearing does not affect outcome after the Endoscopic Distal Soft Tissue Procedure for Hallux Valgus Correction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Randomised control trial on the optimal duration of non-weight-bearing walking after hallux valgus surgery.
Ling SKK, Wu YM, Li C, Lui TH, et al · · 2020 · cited 8× · PMID 32489861 · DOI 10.1016/j.jot.2020.04.009

Verify or expand the search:

Other North District Hospital trials

Trials by the same sponsor.

NCT06380023 — An Investigation Into the Dispersion Pattern During Coughing and Open Nasopharyngeal Suction Using Various Barrier Devic · completed
NCT05506202 — Basic Body Awareness Therapy (BBAT) for Patients With Chronic Obstructive Pulmonary Disease · NA · completed
NCT04003870 — Orthotics and Achilles Load in Runners · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03340415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by North District Hospital
Last refreshed: 24 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03340415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03340415

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other North District Hospital trials

Verify against primary sources